Atria Wealth Solutions Inc. Sells 2,703 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Atria Wealth Solutions Inc. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,461 shares of the biopharmaceutical company’s stock after selling 2,703 shares during the period. Atria Wealth Solutions Inc.’s holdings in Gilead Sciences were worth $5,400,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. nVerses Capital LLC bought a new stake in Gilead Sciences during the 3rd quarter worth approximately $25,000. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the last quarter. Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences during the 4th quarter worth approximately $28,000. Finally, Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter valued at $29,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 713,000 shares of company stock worth $67,945,181 in the last quarter. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $107.65 on Thursday. The business’s 50-day moving average price is $94.70 and its two-hundred day moving average price is $88.23. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $107.81. The company has a market capitalization of $134.16 billion, a price-to-earnings ratio of 290.95, a P/E/G ratio of 0.87 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts expect that Gilead Sciences, Inc. will post 7.94 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.94%. Gilead Sciences’s dividend payout ratio (DPR) is presently 832.43%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GILD shares. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. UBS Group increased their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. The Goldman Sachs Group increased their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Finally, Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $102.08.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.